

School: School of Science

Program/s: **BMS**

Year: 2nd Semester: 3

Examination: End Semester Examination

Examination year: December - 2021

Course Code: BM206

Course Name: Good Laboratory Practices

Date: 10/12/2021

Time: 8:30 am to 10:30 pm

Total Marks: 40 Total Pages: 2

Instructions:

→ Write each answer on a new page

→ Draw neat and well-labelled diagrams wherever required

* COs=Course Outcome mapping. # BTL=Bloom's Taxonomy Level mapping

a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.	Q. No.		Details	Mark s	COs	BTL#
a. Stringent operating procedures b. Principles for planning, performing, monitoring and reporting of studies c. Proper management of data d. Management of scientific resources 2. The purpose of the corrective and preventive action subsystem is a. To prepare SOPs b. To manage logbooks c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3	Q.1	A.		13		
b. Principles for planning, performing, monitoring and reporting of studies c. Proper management of data d. Management of scientific resources 2. The purpose of the corrective and preventive action subsystem is a. To prepare SOPs b. To manage logbooks c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to study efficacy of the drug d. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.						
c. Proper management of data d. Management of scientific resources 2. The purpose of the corrective and preventive action subsystem is a. To prepare SOPs b. To manage logbooks c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.	-					
d. Management of scientific resources 2. The purpose of the corrective and preventive action subsystem is			 b. Principles for planning, performing, monitoring and reporting of studies 	9.1		* ^
2. The purpose of the corrective and preventive action subsystem is	-11		c. Proper management of data			
a. To prepare SOPs b. To manage logbooks c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3			d. Management of scientific resources			
a. To prepare SOPs b. To manage logbooks c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3	r		2. The purpose of the corrective and preventive action subsystem is			
c. To collect and analyze information to identify product and quality problems d. To give training to personnel for better output 3	4		a. To prepare SOPs			
d. To give training to personnel for better output 3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.						
d. To give training to personnel for better output 3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			c. To collect and analyze information to identify product and quality			
3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			problems			= 7
3 is submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy while Phase IIB is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.		8 -44	d. To give training to personnel for better output			
clinical trials have been completed for a license to market the drug for a specified indication. a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			3 is submitted by the manufacturer of a drug to the FDA - after		CO	at e
a. New drug application b. Investigational new drug c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.		, i	clinical trials have been completed for a license to market the drug for a			BTL1,
c. Institutional Review Board d. Rational drug design 4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.		lei			3,4,	2,3
4. Which of the following statements is true about clinical studies a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			- 11 and		5	
a. Phase IIA is specifically designed to assess dosing requirements while Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			4. Which of the following statements is true about clinical studies	25		
Phase IIB is specifically designed to study efficacy b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			a. Phase IIA is specifically designed to assess dosing requirements while			
b. Phase IIA is specifically designed to study efficacy while Phase IIB is specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			Phase IIB is specifically designed to study efficacy			
specifically designed to assess dosing requirements c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			b. Phase IIA is specifically designed to study efficacy while Phase IIB is			
c. Phase II A and B studies are done to study the efficacy of the drug d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			specifically designed to assess dosing requirements	E-		
d. Phase II A and B studies are done to assess dosing requirements B. Fill in the blanks (5M) 6. A design is a design in which each patient receives one and only one treatment in a random fashion.			c. Phase II A and B studies are done to study the efficacy of the drug			
6. A design is a design in which each patient receives one and only one treatment in a random fashion.			d. Phase II A and B studies are done to assess dosing requirements			
6. A design is a design in which each patient receives one and only one treatment in a random fashion.		В.	Fill in the blanks (5M)			
one treatment in a random fashion.						3
		-	one treatment in a random fashion		a 1: 1	
			7. The drug that blocks the activity of its target is known as			
8. In cell lines, cells have infinite lifespan			8. In cell lines cells have infinite liferance		1	

	A			
	9. The use of the drug created by Massengil caused kidney failure,			
	stoppage of urine, severe abdominal pain, nausea, vomiting, stupor, and			
	convulsions in patients			
	10. A spare parts gives information about the stock, cost and ordering			
	information			
	C. State whether true or false with justification (4M)			
	1. Anchorage dependency means that cells have finite life span			
	2. The FDA is responsible for protecting and promoting public health through			
	the control and supervision of food safety, vaccines, biopharmaceuticals,			
	animal foods & feed and veterinary products.			
	3. IND approval filing is followed by establishment of the effective and toxic			
	doses.			
	4. Methods of synthesis, fabrication, or derivation of test and control articles			
0.2	should be documented for FDA inspection.		-	
Q.2	Answer the following in one or two sentences <u>ANY FIVE</u> (5 questions X 2 Marks=10 Marks)	10		
	1. What are the features of a good log book?			
	2. What is the difference between direct and indirect drug design?		СО	
	3. How do diagnostic trials differ from prevention trials?			
	4. What are the roles of an Institutional Review Board?		1,2,	BTI
	5. Why are bioassays important?		3,4,	2,3
	6. If you are given the task of equipment management, what will be your		5	
	responsibilities?	2		
Q.3	Answer the following in detail (4 questions X 3 marks=12 Marks)	12		
	1. Discuss the different phases of clinical trials.		00	
	2. Discuss the different phases of clinical trials.		CO	
	3. What are lean labs? What are the advantages of a lean lab?		1,2,	BTL
	4. You have received a product which has issues with its quality. What steps will		3,4,	2,3
	and the received a product which has issues with its quality. What steps will		5	
	you take?			1
).4		5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5	5	2 =	* ·
Q.4		5		
2.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B	5		
2.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks)	5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B	5		- 19 m
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Active Drug	5		8
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B	5	CO	ВТІ
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Active Drug	5	CO 5	
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Randomization	5	CO 5	BTL: 2,3
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Active Drug Randomization Treatment B Treatment A Treatment B Treatment B Active Drug	5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Randomization	5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Randomization Treatment B Placebo Placebo Treatment A Placebo	5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Active Drug Randomization Treatment B Active Drug Treatment A Placebo Period 1 Wash Out Period 2	5		
Q.4	Q4. What does the given image depict? Write the benefits of the wash-out period (5 Marks) Treatment A Treatment B Active Drug Randomization Treatment B Placebo Placebo Treatment A Placebo	5		BTL1 2,3